Capricor Therapeutics files breach-of-contract lawsuit against US partner NS Pharma

With an FDA decision date looming for its Duchenne muscular dystrophy (DMD) treatment deramiocel, Capricor Therapeutics has filed a lawsuit against its U.S. commercial partner, NS Pharma, and its parent company, Nippon Shinyaku.